BlossomHill Therapeutics (NASDAQ:BLSM) Reaches New 1-Year Low – Time to Sell?

Posted by George Bondi on Nov 2nd, 2026

BlossomHill Therapeutics, Inc. (NASDAQ:BLSM – Get Free Report)’s stock price reached a new 52-week low during trading on Monday. The company traded as low as $12.28 and last traded at $12.42, with a volume of 140,761 shares trading hands. The stock had previously closed at $13.75.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the company. JPMorgan Chase & Co. started coverage on BlossomHill Therapeutics in a report on Tuesday, September 1st. They issued an “overweight” rating and a $28.00 price target for the company. HC Wainwright reissued a “buy” rating on shares of BlossomHill Therapeutics in a report on Wednesday, September 30th. Wall Street Zen upgraded BlossomHill Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, October 24th. Zacks Research raised BlossomHill Therapeutics to a “hold” rating in a research note on Wednesday, September 2nd. Finally, Leerink Partners increased their target price on BlossomHill Therapeutics from $36.00 to $40.00 and gave the company an “outperform” rating in a research report on Monday, September 21st. Five analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $35.00.

Read Our Latest Stock Report on BLSM

BlossomHill Therapeutics Trading Down 9.7%

The firm’s 50-day moving average price is $18.90.

BlossomHill Therapeutics (NASDAQ:BLSM – Get Free Report) last released its quarterly earnings results on Friday, September 18th. The company reported ($8.75) earnings per share for the quarter, missing the consensus estimate of ($0.84) by ($7.91). Research analysts expect that BlossomHill Therapeutics, Inc. will post -5.54 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, General Counsel Vincent Liptak purchased 2,500 shares of the company’s stock in a transaction that occurred on Friday, August 7th. The stock was purchased at an average cost of $15.80 per share, for a total transaction of $39,500.00. Following the completion of the transaction, the general counsel owned 109,212 shares of the company’s stock, valued at $1,725,549.60. This trade represents a 2.34% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director John P. Schmid acquired 6,000 shares of BlossomHill Therapeutics stock in a transaction that occurred on Monday, August 10th. The stock was purchased at an average cost of $16.00 per share, with a total value of $96,000.00. Following the completion of the purchase, the director owned 6,000 shares in the company, valued at $96,000. The trade was a ∞ increase in their position. The SEC filing for this purchase provides additional information. Over the last 90 days, insiders have bought 1,573,900 shares of company stock valued at $25,181,900.

BlossomHill Therapeutics Company Profile

(Get Free Report)

BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop small molecule medicines which address significant unmet medical needs in cancer treatment. The company’s lead clinical programs include BH-30643. BlossomHill Therapeutics Inc is headquartered in San Diego, California.